Novartis, Bayer among animal-health bidders

At least three drug companies--including Novartis and Boehringer Ingelheim--have made initial bids and remain in the race for animal health operations put on sale by Merck ($MRK) and Sanofi-Aventis ($SNY), sources tell Reuters. Report

Suggested Articles

Gilead Sciences has found a new chief financial officer in an appointment that has mergers and acquisitions written all over it.

Pfizer's role as the hero in ramping up production of a chemo drug badly needed by pediatric oncologists is a turnabout for the drugmaker.

Johnson & Johnson is dealing with $2 billion in patent losses in 2019, but has 10 drugs growing at double-digit percentages, executives said Tuesday.